Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will issue its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Keryx Biopharmaceuticals, Inc. (NASDAQ KERX) opened at $6.37 on Friday. The company has a debt-to-equity ratio of 4.88, a current ratio of 5.76 and a quick ratio of 5.16.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 16th. ValuEngine lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. BidaskClub raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Maxim Group set a $9.00 price objective on Keryx Biopharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 price objective (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. Keryx Biopharmaceuticals has a consensus rating of “Hold” and a consensus price target of $7.48.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.